Clinical trials: Nutrition Disorder
Overweight, Obesity
A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes
The main purpose of this study is to evaluate the efficacy and safety of eloralintide compared with placebo for body weight reduction in participants with overweight or obesity and type 2 diabetes.
- Trial name
- ENLIGHTEN-2 (NCT07282600)
- Testing
- Eloralintide
- Where
- 143 sites in United States, China and 11 more
- Volunteers
- 1,035 people
- Sponsor
- Eli Lilly and Company
Obesity, Overweight
A Regulatory Post-marketing Surveillance (rPMS) Study to Evaluate the Safety and Effectiveness of Saxenda®(Liraglutide 3.0 mg) in Obese Patients and Overweight Patients With Obesity-related Comorbidities in Routine Clinical Practice in Korea.
The purpose of this study is to collect information about the safety and effectiveness of Saxenda® in obese patients and overweight patients with obesity-related comorbidities.
- Trial name
- NCT03560336
- Testing
- Liraglutide
- Where
- 28 sites in South Korea
- Volunteers
- 758 people
- Sponsor
- Novo Nordisk A/S
Obesity or Overweight, Weight-Related Comorbidity
A Study to Evaluate Effect of AZD6234 as an Adjunct to Incretin-based Therapies in Adult Participants With Obesity or Overweight With Weight-related Comorbidity With or Without Type 2 Diabetes Mellitus
The study will evaluate how well AZD6234 works and how safe it is in adults with excess weight or obesity. Efficacy of AZD6234 will be compared to placebo in percent body weight change from baseline at 68 weeks of treatment.
- Conditions
- Obesity or Overweight, Weight-Related Comorbidity, With/Without Diabetes Mellitus, Type 2
- Trial name
- SELENE 3 (NCT07776509)
- Testing
- Lenbelintide
- Where
- 96 sites in United States, Argentina and 9 more
- Volunteers
- 500 people
- Sponsor
- AstraZeneca
Obesity
Phase 1 Study of NGM313 in Healthy Adult Participants
The purpose of this study is to determine the safety and tolerability of NGM313, both single dose and multiple doses, in normal healthy overweight and obese adult participants.
- Trial name
- NCT02708576
- Testing
- NGM313
- Where
- Australia
- Volunteers
- 151 people, healthy volunteers welcome
- Sponsor
- NGM Biopharmaceuticals, Inc
Obesity, Roux-en-Y Gastric Bypass
A Registry of Laparoscopic Bariatric Surgery Using Stapling Devices: Observation of Safety and Clinical Efficacy
The purpose of this observational registry is to evaluate the safety and the clinical efficacy of laparoscopic bariatric surgery using stapling devices (easyEndoTM Universal Linear Cutting Stapler and reloads from Ezisurg…
- Conditions
- Obesity, Roux-en-Y Gastric Bypass, Gastrostomy, Nissen Sleeve
- Trial name
- STAP-JOLI (NCT04808206)
- Testing
- easyEndoTM Universal Linear Cutting Stapler and reloads (Ezisurg Medical)
- Where
- 3 sites in Belgium
- Volunteers
- 150 people
- Sponsor
- Duomed
Overweight and Obesity, Body Weight Changes
Microalgae Extract Phaeosol Combined to Exercise in Healthy Overweight Women : Efficacy on Body Weight Management
PhaoeSOL (Microphyt, Baillargues, France) is a microalgae-based nutritional ingredient developed with a patented production process that has New Dietary Ingredient (NDI) status from the FDA (#1120).
- Conditions
- Overweight and Obesity, Body Weight Changes, Healthy Lifestyle, Exercise
- Trial name
- PHAEOSOL-ONE (NCT04761406)
- Testing
- Phaeosol group
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Microphyt
Obesity
Effects of PrimaVie and Exercise Training on Human Skeletal Muscle (PrimaVie)
PrimaVie (Natreon Inc), is a a purified and standardized shilajit extract for nutraceutical use. Research indicates that PrimaVie® has targeted action for increasing energy, revitalization and anti-aging.
- Trial name
- NCT02026414
- Testing
- PrimaVie, Exercise
- Where
- United States
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- Sanni Raju
Obesity, Metabolic Syndrome
Association of Genes to Resistance to Weight Loss in Obese Patients
The overall goal of this study is to determine whether variations in the perilipin, and several other, genes would be a useful tool for physicians who are caring for morbidly obese patients to guide therapy.
- Conditions
- Obesity, Metabolic Syndrome, Dyslipidemia
- Trial name
- NCT00858221
- Where
- United States
- Volunteers
- 824 people
- Sponsor
- Interleukin Genetics, Inc.
Nutritional Status
Pharmacokinetics and Safety of GSK1325756 in Elderly Subjects and Adult Subjects of in the Fed and Fasted States and in the Presence of a Proton Pump Inhibitors
GSK1325756 is a potent, competitive, selective and reversible CXCR2 receptor antagonist that is being developed as a once-daily oral anti-inflammatory medication for the treatment of chronic obstructive pulmonary disease (COPD).
- Trial name
- NCT01209104
- Testing
- GSK1325756
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Overweight or Obesity
Safety and Drug Concentrations of REGN20934 in Adults With Overweight or Obesity
This study will test a study drug called REGN20934 to see how safe and well tolerated this drug is, as well as how the drug is processed in the body for participants with overweight or obesity.
- Trial name
- NCT07594093
- Testing
- REGN20934
- Where
- United States
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Regeneron Pharmaceuticals
Overweight or Obesity
Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IBI362 in Overweight or Obesity Subjects
This trial is conducted in China. The aim of this trial is to investigate Safety, Tolerability, PK and PD for Multiple Doses of IBI362 in Overweight or Obese Male and Female Subjects.
- Trial name
- NCT04440345
- Testing
- IBI362
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Obesity
To Assess the Effect of Lorcaserin Hydrochloride on Energy Metabolism and Food Intake
The purpose of this study is to evaluate the effect of lorcaserin on energy metabolism and food intake in obese and overweight patients.
- Trial name
- TULIP (NCT00829140)
- Testing
- Lorcaserin 10mg BID
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- Eisai Inc.
Disease Related Malnutrition
Tolerance and Acceptability of an Oral Nutrition Supplement
The goal of this study is to learn whether a new oral nutritional supplement is acceptable to adults who are malnourished, or at risk of malnutrition, and need nutritional support.
- Trial name
- NCT07904715
- Testing
- Oral nutritional supplementation
- Where
- United Kingdom
- Volunteers
- 20 people
- Sponsor
- Aymes International Limited
Morbid Obesity
Post Implantation/Post Market Evaluation of the Swedish Adjustable Gastric Band
The purpose of the study is to evaluate the long term safety of the Swedish Adjustable Gastric Band (SAGB) in subjects with an SAGB in place.
- Trial name
- SAGB-PM (NCT00543140)
- Testing
- REALIZE™ Swedish Adjustable Gastric Band
- Where
- 8 sites in United States
- Volunteers
- 303 people
- Sponsor
- Ethicon Endo-Surgery
Obese, Overweight
A Study of SA030 Injection in Overweight or Obese Participants
This study is the first time SA030 is being given to people. The goal is to understand how safe it is, how well it is tolerated, and how the body processes and responds to a single dose of SA030 in individuals who are overweight…
- Trial name
- NCT07479862
- Testing
- SA030 Injection
- Where
- 2 sites in Australia
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Suzhou Siran Biotechnology Co.,Ltd.
Obesity and Cardiovascular Risk
A Phase 2 Study to Evaluate the Pharmacodynamics, Safety and Tolerability of BGE-102 in Participants With Obesity and Cardiovascular Risk Factors
The purpose of this study is to learn about the effects of BGE-102 on blood biomarkers including hsCRP, which is a lab value used to measure inflammation.
- Trial name
- QUELL-CV (NCT07656727)
- Testing
- Oral BGE-102
- Where
- 17 sites in United States, Puerto Rico
- Volunteers
- 160 people
- Sponsor
- BioAge Labs, Inc.
Malnutrition
Oral Nutritional Supplementation in Hospital Patients
The study objective is to evaluate the benefits of Oral Nutritional Supplementation (ONS) plus Dietary Counseling (DC) in newly admitted hospital subjects with moderate or severe malnutrition.
- Trial name
- NCT01641770
- Testing
- Nutritional beverage 10003RF, Dietary Counseling
- Where
- 13 sites in India
- Volunteers
- 212 people
- Sponsor
- Abbott Nutrition
Obesity, Obesity, Abdominal
Impact of the Use of FeelWell™ Compression Garment on Individuals With a BMI ≥35
To assess the effect of wearing a custom-fitted, FDA-registered, Class I device, compression garment (Obesinov, S.A.R.L.) by an individual with a BMI ≥ 35 on his/her day-to-day quality of life over a period of one year.
- Conditions
- Obesity, Obesity, Abdominal, Mobility Limitation, Quality of Life
- Trial name
- NCT03798873
- Testing
- FeelWell™ Compression garment, Increase Mobility
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Feelwell Compression
Essential Fatty Acid Deficiency (EFAD)
Pediatric Study to Evaluate Risk of Developing Essential Fatty Acid Deficiency When Receiving Clinolipid or Standard-of-Care Lipid Emulsion (Part A)
This will be a descriptive study designed to evaluate the propensity for hospitalized pediatric patients treated adequately with Clinolipid or standard of care (Intralipid) from 7 up to 90 days to develop Essential Fatty Acid…
- Trial name
- NCT04555044
- Testing
- Clinolipid, Intralipid
- Where
- 9 sites in United States
- Volunteers
- 101 people
- Sponsor
- Baxter Healthcare Corporation
Intensive Care Unit, Coronary Artery Bypass Grafting (CABG)
Intravenous Fish Oil Based Lipid Emulsion to Enhance Recovery in High-Risk Cardiac Surgery Patients
The MODIFY CSX study is a prospective, randomized, placebo-controlled trial conducted in heart centers in Germany and Italy. A total of 550 high-risk cardiac surgery patients will receive either 0.20 g fish oil/kg body weight…
- Conditions
- Intensive Care Unit, Coronary Artery Bypass Grafting (CABG), High Risk Patients, Cardiopulmonary Bypass
- Trial name
- MODIFY CSX (NCT06279793)
- Testing
- Fish Oil, Intravenous 0.9% Sodium Chloride
- Where
- 10 sites in Germany
- Volunteers
- 550 people
- Sponsor
- GCP-Service International West GmbH
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.